Alixorexton

Small molecule

Also known as ALKS 2680

Phase 3underway

Evidence outlook · registrational

Narcolepsy: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2027-05. The sponsor reported topline results of a Phase 2 study on 2025-11-12 (Phase 2 Vibrance-2 (NCT06555783) met its dual primary endpoints in narcolepsy type 2); that is not the registrational readout.

Also in development:Idiopathic Hypersomnia · Phase 2/3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Narcolepsy
Phase 2/3 (1)
Idiopathic Hypersomnia
Phase 2 (3)
Idiopathic Hypersomnia
NCT06843590 · Alkermes, Inc.
2025-05-22 – 2026-11 · Idiopathic Hypersomnia
What this study did
Narcolepsy
NCT06555783 · Alkermes, Inc.
2024-07-26 – 2025-11-21 · Narcolepsy Type 2
What this study did
NCT06358950 · Alkermes, Inc.
2024-03-24 – 2025-07-31 · Narcolepsy Type 1
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Idiopathic Hypersomnia: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Alixorexton: this drugPhase 2/3Small moleculeOrexin-2 receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Calcium, Magnesium, Potassium And Sodium Oxybates (Xywav)ApprovedSmall moleculeGABA-B receptornot yet gradedNo reviewed efficacy summary in this indication
Pitolisant (Wakix)Phase 3Small moleculeHistamine H3 receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Alixorexton to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Idiopathic HypersomniaActive not recruiting
Est. primary completion 2026-11 · NCT06843590 · CT.gov ↗
What to watch
2027 (3)
May 2027 (2)
Phase 3NarcolepsyRecruiting
Est. primary completion 2027-05 · NCT07455383 · CT.gov ↗
What to watch
Phase 3NarcolepsyRecruiting
Est. primary completion 2027-05 · NCT07502443 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3NarcolepsyRecruiting
Est. primary completion 2027-06 · NCT07540897 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 2/3NarcolepsyRecruiting
Est. primary completion 2030-06 · NCT06767683 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 November 2025Topline resultPhase 2 Vibrance-2 (NCT06555783) met its dual primary endpoints in narcolepsy type 2
21 July 2025Topline resultPhase 2 Vibrance-1 (NCT06358950) met its primary endpoint in narcolepsy type 1